The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The Caerphilly Study



      Interleukin-6 (IL-6) is a key pro-inflammatory cytokine which mediates expression of several ‘downstream’ inflammatory markers and may play a role in atherothrombosis. However, it is not yet known whether IL-6 plays a role in mediating the associations of each marker with risk of coronary heart disease (CHD) or ischaemic stroke (IS).

      Methods and results

      We examined the role of IL-6 and several “downstream” markers of inflammation (leucocyte counts, plasma and serum viscosity, fibrinogen, C-reactive protein, α1-antitrypsin and α2-macroglobulin) with risk of subsequent CHD, IS, and a combined endpoint (CHD/IS) in a population of British men. 2208 men aged 45–64 years were followed for a median of 13.4 years and 486 men had experienced a cardiovascular event. In age-adjusted analyses, most inflammatory markers were significantly associated with risk of CHD or CHD/IS, but for IS associations were weaker. On multivariable analyses, including conventional risk factors, associations of serum viscosity, α2-macroglobulin and leucocyte count became non-significant for CHD and CHD/IS, while no inflammatory marker retained a significant association with risk of IS. In contrast, IL-6 retained a significant association with CHD and CHD/IS and, after adjustment for IL-6, hazard ratios for downstream inflammatory markers were attenuated to non-significance.


      These findings suggest that IL-6 may play a role in mediating the associations of circulating inflammatory markers with risk of CHD in men. Further studies are required to assess whether this is also the case for risk of IS, and for CHD/IS in women.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Packard R.R.
        • Libby P.
        Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction.
        Clin Chem. 2008; 54: 24-38
        • Yarnell J.W.
        • Baker I.A.
        • Sweetnam P.M.
        • et al.
        Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies.
        Circulation. 1991; 3: 836-844
        • Yarnell J.W.G.
        • Patterson C.C.
        • Sweetnam P.M.
        • Lowe G.D.O.
        Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies.
        Eur Heart J. 2004; 25: 1049-1056
        • Lowe G.D.O.
        • Sweetnam P.M.
        • Yarnell J.W.G.
        • et al.
        C-reactive protein, fibrin D-dimer, and risk of ischaemic heart disease: the Caerphilly and Speedwell studies.
        Arterioscler Thromb Vasc Biol. 2004; 24: 1-7
        • Elwood P.C.
        • Yarnell J.W.G.
        • Sweetnam P.M.
        • O’Brien J.R.
        Plasma viscosity and fibrinogen in The Caerphilly and Speedwell Studies.
        Clin Hemorheol. 1992; 12: 545-548
        • Danesh J.
        • Lewington S.
        • Thompson S.G.
        • et al.
        Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
        JAMA. 2005; 294: 1799-1809
        • Danesh J.
        • Collins R.
        • Peto R.
        • Lowe G.D.O.
        Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease.
        Eur Heart J. 2001; 21: 515-520
        • Wheeler J.G.
        • Mussolino M.E.
        • Gillum R.
        • Danesh J.
        Associations between differential leucocyte count and incident coronary heart disease: 1794 incident cases from seven prospective studies of 30,374 individuals.
        Eur Heart J. 2004; 25: 1287-1292
        • Danesh J.
        • Collins R.
        • Appleby P.
        • Peto R.
        Association of fibrinogen, C-reactive protein, albumin, or leucocyte count with coronary heart disease: meta-analyses of prospective studies.
        JAMA. 1998; 279: 1477-1482
        • Danesh J.
        • Wheeler J.G.
        • Hirschfield G.M.
        • et al.
        C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
        New Engl J Med. 2004; 350: 1387-1397
        • Kerr R.
        • Stirling D.
        • Ludlam C.A.
        Interleukin 6 and haemostasis.
        Br J Haematol. 2001; 115: 3-12
        • Danesh J.
        • Kaptoge S.
        • Mann A.G.
        • et al.
        Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.
        PLoS Med. 2008; 5: e78
        • Smith A.
        • Patterson C.C.
        • Yarnell J.W.G.
        • et al.
        Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study.
        Circulation. 2005; 112: 3080-3087
        • Yu S.
        • Lowe G.D.O.
        • Yarnell J.W.G.
        • Sweetnam P.M.
        Resonance-thrombography of the haemostatic process in relation to risk of incident coronary heart disease: 9 years follow-up in the Caerphilly Prospective Heart Disease Study.
        Br J Haematol. 2004; 126: 385-391
        • Deaton C.D.
        • Maxwell K.W.
        • Smith R.S.
        • Creveling R.L.
        Use of laser nephelometry in the measurement of serum proteins.
        Clin Chem. 1976; 22: 1465-1471
        • Schafer J.L.
        Multiple imputation: a primer.
        Stat Methods Med Res. 1999; 8: 3
        • Royston P.
        Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring.
        Stata J. 2007; 7: 445-464
        • Woodward M.
        • Rumley A.
        • Tunstall-Pedoe H.
        • Lowe G.D.O.
        Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease.
        Br J Haematol. 1999; 104: 246-257
        • Bermudez E.A.
        • Rifai N.
        • Buring J.
        • Manson J.E.
        • Ridker P.M.
        Interrelationships among circulating interleukin 6, C-reactive protein, and traditional cardiovascular risk factors in women.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1668-1673
        • Wannamethee S.G.
        • Whincup P.H.
        • Rumley A.
        • Lowe G.D.O.
        Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men.
        J Thromb Haemost. 2007; 5: 1637-1643
        • Welsh P.
        • Woodward M.
        • Rumley A.
        • Lowe G.
        Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study.
        Br J Haematol. 2008; 141: 852-861
        • Tzoulaki I.
        • Murray G.D.
        • Price J.F.
        Hemostatic factors, inflammatory markers and progressive peripheral atherosclerosis: the Edinburgh Artery Study.
        Am J Epidemiol. 2006; 163: 334-341
        • Saremi A.
        • Anderson R.J.
        • Luo P.
        • et al.
        Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT).
        Atherosclerosis. 2009; 203: 610-614
        • Baker I.A.
        • Pickering J.
        • Elwood P.C.
        • Bayer A.
        • Ebrahim S.
        Fibrinogen, viscosity and white blood cell count predict myocardial, but not cerebral infarction: evidence from the Caerphilly and Speedwell cohort.
        Thromb Haemost. 2002; 87: 421-425
        • Ridker P.M.
        Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).
        Thromb Haemost. 2009; 7: 332-339